News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Jaguar Health Inc. Analyst Christian Orquera lowers target price to USD 7.50 due to licensing agreement with Future Pak and focus on core drug development -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar Health, Inc. provides updates on rare disease program for crofelemer, focusing on intestinal failure treatment milestones, Orphan Drug Designation, and global development efforts -
